Joseph Zhou1, Anil Poudel2, Prashanth Chandramani-Shivalingappa2, Biao Xu3, Ryan Welchko2, Lixin Li4. 1. College of Medicine, Central Michigan University, Mount Pleasant, MI, 48859, USA. 2. Department of Physician Assistant, College of Health Professions, Central Michigan University MI, Mount Pleasant, MI, 48859, USA. 3. Department of Cardiology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China. 4. Department of Physician Assistant, College of Health Professions, Central Michigan University MI, Mount Pleasant, MI, 48859, USA. li6l@cmich.edu.
Abstract
PURPOSE: Glucagon like peptide-1 (GLP-1) is produced to induce postprandial insulin secretion. Liraglutide, a full agonist of the GLP-1 receptor, has a protective effect on weight gain in obese subjects. Brown adipose tissue plays a major role in the control of energy balance and is known to be involved in the weight loss regulated by liraglutide. The putative anti-obesity properties of liraglutide and the cell signaling pathways involved were examined. METHODS: Four groups of C57/BL6 mice fed with chow or HFHS diet were injected with either liraglutide or vehicle for four weeks. Western blotting was used to analyze protein expression. RESULTS: Liraglutide significantly attenuated the weight gain in mice fed with HFHS diet and was associated with significant reductions of epididymal fat and inguinal fat mass. Furthermore, liraglutide significantly upregulated the expression of brown adipose-specific markers in perigonadal fat in association with upregulation of AMPK-SIRT-1-PGC1-α cell signaling. However, elevation of brown fat markers in skeletal muscle was only observed in HFHS diet fed mice after liraglutide treatment, and AMPK-SIRT-1 cell signaling is not involved in this process. CONCLUSIONS: the anti-obesity effect of liraglutide occurs through adaptive thermogenesis and may act through different cell signaling pathways in fat and skeletal muscle tissue. Liraglutide induces beige fat development partially through the AMPK-SIRT-1-PGC1-α cell signaling pathway. Therefore, liraglutide is a potential medication for obesity prevention and in targeting pre-diabetics.
PURPOSE:Glucagon like peptide-1 (GLP-1) is produced to induce postprandial insulin secretion. Liraglutide, a full agonist of the GLP-1 receptor, has a protective effect on weight gain in obese subjects. Brown adipose tissue plays a major role in the control of energy balance and is known to be involved in the weight loss regulated by liraglutide. The putative anti-obesity properties of liraglutide and the cell signaling pathways involved were examined. METHODS: Four groups of C57/BL6 mice fed with chow or HFHS diet were injected with either liraglutide or vehicle for four weeks. Western blotting was used to analyze protein expression. RESULTS: Liraglutide significantly attenuated the weight gain in mice fed with HFHS diet and was associated with significant reductions of epididymal fat and inguinal fat mass. Furthermore, liraglutide significantly upregulated the expression of brown adipose-specific markers in perigonadal fat in association with upregulation of AMPK-SIRT-1-PGC1-α cell signaling. However, elevation of brown fat markers in skeletal muscle was only observed in HFHS diet fed mice after liraglutide treatment, and AMPK-SIRT-1 cell signaling is not involved in this process. CONCLUSIONS: the anti-obesity effect of liraglutide occurs through adaptive thermogenesis and may act through different cell signaling pathways in fat and skeletal muscle tissue. Liraglutide induces beige fat development partially through the AMPK-SIRT-1-PGC1-α cell signaling pathway. Therefore, liraglutide is a potential medication for obesity prevention and in targeting pre-diabetics.
Authors: Li-Xin Li; Patrick E MacDonald; Diane S Ahn; Gavin Y Oudit; Peter H Backx; Patricia L Brubaker Journal: Endocrinology Date: 2006-03-30 Impact factor: 4.736
Authors: Kirsi A Virtanen; Martin E Lidell; Janne Orava; Mikael Heglind; Rickard Westergren; Tarja Niemi; Markku Taittonen; Jukka Laine; Nina-Johanna Savisto; Sven Enerbäck; Pirjo Nuutila Journal: N Engl J Med Date: 2009-04-09 Impact factor: 91.245
Authors: Meritxell Rosell; Myrsini Kaforou; Andrea Frontini; Anthony Okolo; Yi-Wah Chan; Evanthia Nikolopoulou; Steven Millership; Matthew E Fenech; David MacIntyre; Jeremy O Turner; Jonathan D Moore; Edith Blackburn; William J Gullick; Saverio Cinti; Giovanni Montana; Malcolm G Parker; Mark Christian Journal: Am J Physiol Endocrinol Metab Date: 2014-02-18 Impact factor: 4.310
Authors: Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney Journal: Endocr Rev Date: 2020-04-01 Impact factor: 19.871
Authors: Joanne M Donkers; Reinout L P Roscam Abbing; Michel van Weeghel; Johannes H M Levels; Anita Boelen; Alfred H Schinkel; Ronald P J Oude Elferink; Stan F J van de Graaf Journal: Cell Mol Gastroenterol Hepatol Date: 2020-04-21